Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. by Scheen, André et al.
Published in : Diabetes/Metabolism Research & Reviews (2010) 
Status : Postprint (Author’s version) 
 
Efficacy and safety of saxagliptin in combination with metformin compared 
with sitagliptin in combination with metformin in adult patients with type 2 
diabetes mellitus 
 
André J. Scheen1 , Guillaume Charpentier2 , Carl Johan Östgren3 , Åsa Hellqvist4 , Ingrid Gause-Nilsson4 
1 University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, 
CHU Liège, Liège, Belgium 
2 Endocrinology-Diabetology Unit, Corbeil-Essonnes Hospital, Essonnes, France 
3 Department of Medical and Health Sciences, Linköping University, Linköping, Sweden 
4 AstraZeneca, Research & Development, Mölndal, Sweden 
 
ABSTRACT 
Background Dipeptidyl peptidase-4 inhibitors improve glycaemic control in patients with type 2 diabetes 
mellitus when used as monotherapy or in combination with other anti-diabetic drugs (metformin, sulphonylurea, 
or thiazolidinedione). This 18-week, phase 3b, multicentre, double-blind, non-inferiority trial compared the 
efficacy and safety of two dipeptidyl peptidase-4 inhibitors, saxagliptin and sitagliptin, in patients whose 
glycaemia was inadequately controlled with metformin. 
Methods Adult type 2 diabetes mellitus patients (N = 801) with glycated haemoglobin (HbA1c) 6.5-10% on 
stable metformin doses (1500-3000 mg/day) were randomized 1:1 to add-on 5 mg saxagliptin or 100 mg 
sitagliptin once daily for 18 weeks. The primary efficacy analysis was a comparison of the change from baseline 
HbA1c at week 18 in per-protocol patients. Noninferiority was concluded if the upper limit of the two-sided 95% 
confidence interval of the HbA1c difference between treatments was <0.3%. 
Results The adjusted mean changes in HbA1c following the addition of saxagliptin or sitagliptin to stable 
metformin therapy were -0.52 and -0.62%, respectively. The between-group difference was 0.09% (95% 
confidence interval, -0.01 to 0.20%), demonstrating noninferiority. Both treatments were generally well 
tolerated; incidence and types of adverse events were comparable between groups. Hypoglycaemic events, 
mostly mild, were reported in approximately 3% of patients in each treatment group. Body weight declined by a 
mean of 0.4 kg in both groups. 
Conclusions Saxagliptin added to metformin therapy was effective in improving glycaemic control in patients 
with type 2 diabetes mellitus inadequately controlled by metformin alone; saxagliptin plus metformin was 
noninferior to sitagliptin plus metformin, and was generally well tolerated. 




According to statements by the American Diabetes Association/European Association for the  Study of Diabetes 
and the American Association of Clinical Endocrinologists/American College of Endocrinology, metformin is 
recommended (unless specifically contraindicated) as a first-line agent for monotherapy and combination therapy 
for patients with type 2 diabetes mellitus (T2DM). This recommendation is based primarily on metformin's 
glucose-lowering effects, absence of weight gain, generally low level of side effects, and relatively low cost 
[1,2]. However, many patients, particularly those with higher baseline glycated haemoglobin (HbA1c) values, 
may not achieve their glycaemic goals on metformin monotherapy despite titration to maximally tolerated doses, 
and therefore require additional medication [1,3,4]. Patients whose glycaemic control deteriorates over time with 
metformin monotherapy will require additional anti-diabetic medication. Although multiple classes of anti-
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diabetic agents are available, there remains a need for agents with different mechanisms of action that offer 
improved efficacy and/or better tolerability profiles and can be used either as monotherapy or in combination 
treatment regimens (including metformin). 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic agents that increase circulating 
concentrations of the incretin gastrointestinal hormones glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide [5]. The incretins are rapidly released after meals and stimulate glucose-dependent 
insulin secretion. Glucagon-like peptide-1 also inhibits glucagon secretion, thereby attenuating postprandial 
glucose excursions [6]. The DPP-4 inhibitors improve glycaemic control by blocking the rapid inactivation of 
incretins, mainly glucagon-like peptide-1 [7-12]. Sitagliptin (Januvia®, Merck & Co, Inc, Whitehouse Station, 
NJ), the first of the DPP-4 inhibitors approved in the United States, has been used as an adjunct to diet and 
exercise in monotherapy and in combination regimens with other oral anti-diabetic drugs [1,11-13]. 
The mechanism of action of the DPP-4 inhibitors is complementary to that of metformin, which improves insulin 
sensitivity and reduces hepatic glucose production [5]. Hypoglycaemia, weight gain, and edema are generally not 
associated with DPP-4 inhibitor therapy; however, these adverse events have been associated with other anti-
diabetic drug classes that are often used in conjunction with metformin (e.g. sulphonylureas, glinides, 
thiazolidinediones, and insulin) [6]. The low propensity for both DPP-4 inhibitors and metformin to cause 
hypoglycaemia or weight gain makes them an appropriate option for combination therapy in patients who are not 
meeting their glycaemic goals [5]. 
Saxagliptin (Onglyza™, Bristol-Myers Squibb, Princeton, NJ/AstraZeneca, Wilmington, DE) is a potent, 
selective DPP-4 inhibitor, approved as an adjunct to diet and exercise to treat hyperglycaemia in patients with 
T2DM [14-16]. In phase 3 clinical trials, saxagliptin added to a stable dose of metformin, sulphonylurea, or 
thiazolidinedione, or given as initial therapy in combination with metformin, significantly improved glycaemic 
control and was well tolerated in patients with T2DM [7-9,17]. In a 24-week study in patients whose diabetes 
was not adequately controlled by stable metformin doses, adding saxagliptin 2.5, 5, or 10 mg daily reduced 
HbA1c from a baseline of 8.1%, by 0.7, 0.8, and 0.7%, respectively, compared with add-on placebo [7]. 
The present study represents the first head-to-head comparison between two DPP-4 inhibitors, and was designed 
to determine whether saxagliptin is effective and well tolerated in the treatment of T2DM and whether it is 
noninferior to sitagliptin. This 18-week trial evaluated the safety and efficacy of saxagliptin versus sitagliptin, 
each in combination with a stable dose of metformin, with a noninferiority assessment of the primary endpoint, 
in patients with T2DM who had inadequate glycaemic control on metformin alone. 
MATERIALS AND METHODS 
Study design 
This 18-week, multicentre, randomized, double-blind, parallel-group, active-controlled phase 3b trial was 
conducted at 99 sites in Argentina (14), Belgium (11), Denmark (9), France (10), Italy (9), Mexico (4), Norway 
(16), South Africa (12), and Sweden (14). After enrollment, eligible patients entered a 2-week lead-in period, 
during which they received single-blind placebo, open-label metformin, and counselling on dietary and lifestyle 
modifications according to usual clinical practice. The dose of open-label metformin was based on each patient's 
current dose at enrollment, and was to remain stable throughout the study. Patients received metformin at 1500, 
2000, 2500, or 3000 mg/day if their dose at entry was 1500-1999 mg/day, 2000-2499 mg/day, 2500-2550 
mg/day, or >2550 mg/day, respectively. Patients were also given a glucometer and a diary, and were instructed 
to monitor their plasma glucose at least every second day during the lead-in period. After 2 weeks, patients who 
continued to meet eligibility requirements, as defined below, were randomly assigned in a 1:1 ratio to double-
blind treatment with 5 mg saxagliptin once daily (o.d.) or 100 mg sitagliptin o.d. for 18 weeks, while continuing 
open-label metformin. A double-dummy design with matching placebo tablets for saxagliptin or placebo 
capsules for sitagliptin was used to ensure blinding. Dietary and lifestyle modification counselling was 
reinforced during this period, and patients were asked to monitor their plasma glucose at least once weekly. 
Patients returned to the clinic at 4, 8, 12, and 18 weeks for efficacy and safety assessments. 
This study was conducted in accord with the Declaration of Helsinki and in compliance with International 
Conference on Harmonisation/Good Clinical Practice and all applicable regulatory requirements. The study 
protocol and informed consent were approved by the Institutional Review Board or Independent Ethics 
Committee at each study site before that site enrolled any patients. All patients provided written informed 
consent before participating in this trial. The clinical trial registry number of this study was NCT00666458. 
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Patients 
Men and women ≥18 years of age who had been diagnosed with T2DM were eligible to participate if HbA1c 
remained uncontrolled (HbA1c 6.5-10.0%), despite monotherapy with a stable dose of metformin ≥1500 mg for 
at least 8 weeks. Women of childbearing potential were required to have a negative urine pregnancy test, and 
agreed to use adequate contraception throughout the study and for up to 4 weeks after completion. Enrollment of 
patients with HbAic >6.5 to <7.0% was scheduled to stop when the cohort of randomized patients with HbA1c 
values in this range reached approximately 25%. At that point, the lower bound of HbA1c for enrollment was to 
be reset at ≥7.0% for the remainder of the study. This contingency was not implemented because the 25% limit 
was not reached until the study was fully enrolled. 
Patients were excluded if they had received a thiazo-lidinedione within 12 weeks or insulin within 1 year, 
previous treatment with a DPP-4 inhibitor, or were currently receiving treatment with a cytochrome P450 3A4 
inducer, a systemic corticosteroid, or a human immunodeficiency virus anti-viral medication. Patients were also 
excluded if they had type 1 diabetes; a history of diabetic ketoacidosis or hyperosmolar nonketonic coma; New 
York Heart Association class III or IV congestive heart failure; left ventricular ejection fraction ≤40%; a major 
cardiovascular event within the past 6 months; haemoglobinopathy; a recent history of alcohol or drug abuse; or 
any contraindication listed in the package inserts of the study drugs. Other exclusion criteria determined at the 
lead-in visit were serum creatinine ≥133 µmol/L (≥1.5 mg/dL) in men or ≥124µmol/L (≥1.4 mg/dL) in women; 
abnormal liver function, defined as aspartate aminotransferase or alanine aminotransferase >2 times the upper 
limit of normal or total bilirubin >34 µmol/L (>2 mg/dL); creatine kinase ≥3 times the upper limit of normal; or 
a history of positive serologic evidence of infectious liver disease. In addition, patients with clinically significant 
abnormalities identified on physical examination, laboratory testing, or electrocardiogram were excluded if, in 
the judgement of the investigator, the abnormality would compromise patient safety or successful participation in 
the study. 
Patients could be discontinued from the study for the following reasons: voluntary discontinuation; safety; non-
compliance with the study protocol; lost to follow-up; use or need of anti-hyperglycaemic medications other than 
metformin and the study drugs for more than 14 consecutive days (insulin during hospitalization was allowed); 
or severe and/or frequent hypoglycaemic events. Other causes for discontinuation were development of study-
specified discontinuation criteria, including a confirmed fasting plasma glucose (FPG) >15.0mmol/L (>270 
mg/dL) at 4 weeks, >13.3 mmol/L (>240 mg/dL) at 8 weeks, or >12.2 mmol/L (>220 mg/dL) at 12 weeks; 
confirmed absolute lymphocyte count ≤400 cells/µL or thrombocyte count <75 000 cells/µL; or a confirmed 
increase in serum creatinine to ≥133 µmol/L (≥1.5 mg/dL) in men or ≥124 µmol/L (≥1.4 mg/dL) in women. 
Efficacy assessments 
HbA1c and FPG were measured at baseline and at 4, 8, 12, and 18 weeks of the double-blind treatment period; 
fasting insulin, proinsulin, C-peptide, and glucagon were determined at baseline and after 18 weeks. 
The primary efficacy variable was absolute change in HbA1c from baseline to week 18. Secondary efficacy 
variables included proportion of patients achieving a therapeutic glycaemic response (defined as HbA1c ≤ 6.5%); 
proportion of patients with baseline HbA1c ≥ 7.0% achieving a therapeutic glycaemic response (defined as HbA1c 
< 7.0%); change from baseline FPG, insulin, C-peptide, and proinsulin; and change from baseline β-cell 
function, as measured by the homeostasis model assessment-2β [18]. 
Safety assessments 
Adverse events, clinical laboratory testing, physical examinations, and vital signs were monitored at each study 
visit during the double-blind treatment period, and 12-lead electrocardiograms were performed at the first and 
last visits. All adverse events were evaluated by the investigator according to their intensity and potential causal 
relationship to study medication, then coded by the sponsor using the Medical Dictionary for Regulatory 
Activities, version 11.1. Patients also self-monitored their plasma glucose levels and were instructed to record 
symptoms suggestive of hypoglycaemia in their diaries. Hypoglycaemic events were defined in accord with the 
guidelines of the Committee for Proprietary Medicinal Products for clinical investigation of medications for 
treatment of diabetes [19]. A hypoglycaemic adverse event was classified as a major event if it was associated 
with at least one symptom, required external assistance (defined as medical assistance or help from 
family/friend/other) to be resolved, had an associated plasma glucose <3.5 mmol/L (<63 mg/dL), and had 
prompt recovery (defined as the start and stop of the event occurring on the same date). A hypoglycaemic 
adverse event was classified as a minor event if it had at least one symptom recorded with plasma glucose <3.5 
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mmol/L (<63 mg/dL) and no need for assistance, or an asymptomatic plasma glucose measurement <3.5 mmol/L 
(<63 mg/dL). Events suggestive of hypoglycaemia were those with at least one symptom, but with no plasma 
glucose measurement or plasma glucose ≥3.5 mmol/L (≥63 mg/dL). In addition, selected skin disorders were 
defined according to Medical Dictionary for Regulatory Activities preferred terms as being potentially 
correlative to skin findings observed in monkeys treated with saxagliptin. This list was compiled before the study 
was unblinded. 
Statistical analyses 
The primary efficacy analysis evaluated whether saxagliptin plus metformin was noninferior to sitagliptin plus 
metformin in reducing HbA1c from baseline to week 18 in the per-protocol population, which included all 
patients who had no significant protocol deviations and completed the 18-week treatment period. This 
comparison between treatment groups for the adjusted mean change in HbA1c was made using an analysis of 
covariance model, with treatment group as a fixed effect and baseline HbA1c as a covariate. Point estimates and 
two-sided 95% confidence intervals (CIs) for the difference in adjusted mean change from baseline in the two 
treatment groups were estimated from the model, and a conclusion of noninferiority was reached if the upper 
limit of the two-sided 95% CI of the difference in HbA1c change from baseline to week 18 was <0.3%. A 
confirmatory analysis of the adjusted mean change from baseline HbA1c was conducted in the full analysis set 
using a last-observation-carried-forward approach, which included all patients who received at least one dose of 
study medication and had at least one baseline and one postbaseline efficacy data assessment. This analysis used 
an analysis of covariance model, with treatment group as a fixed effect and baseline HbA1c as a covariate. A 
sample size of 710 patients (or 355 per treatment group) was estimated to have 90% power to establish the 
noninferiority between treatment groups at the 5% level, assuming that the standard deviation of the change from 
baseline HbA1c was 1.1%, with a noninferiority limit set at 0.3% and an assumed zero true difference between 
treatment groups. The sample size also assumed that 20% of randomized patients would be excluded from the 
per-protocol analysis set. 
A similar analysis of covariance model was used to compare secondary continuous efficacy variables between 
treatment groups, adjusted for the baseline value of that variable (e.g. changes in FPG from baseline to week 18 
were adjusted for baseline FPG). For categorical variables, such as the proportion of patients achieving a 
therapeutic glycaemic response, the frequency and percentage were calculated, and the percent difference 
between treatments and 95% CI were estimated using the Fisher exact test. No a priori hypotheses were 
proposed for secondary efficacy variables and, therefore, only the 95% CIs are provided for these values. Safety 




Of the 822 patients who entered the lead-in period, 21 patients did not enter the randomized, double-blind 
treatment period. Reasons for these patients not entering the randomized, double-blind treatment period included 
withdrawal of consent, incorrect enrollment, and poor compliance or noncompliance. A total of 801 patients with 
T2DM whose glycaemia remained inadequately controlled with metformin monotherapy were randomly 
allocated to 5 mg saxagliptin o.d. added to ongoing metformin (n = 403 patients) or 100 mg sitagliptin o.d. added 
to ongoing metformin (n = 398) (Figure 1). More than 90% of patients in both treatment groups completed the 
18-week double-blind treatment period. Reasons for discontinuation were generally similar between treatment 
groups, although more patients discontinued from the saxagliptin group than from the sitagliptin group because 
of development of study-specified discontinuation criteria (3.5 versus 1.8%), most commonly FPG >12.2 
mmol/L (>220 mg/dL) at week 12 (2.0 versus 0.8%). 
Patient demographics and baseline characteristics 
Demographic and clinical characteristics of study patients were generally well balanced between treatment 
groups (Table 1). Overall, the study cohort had a mean age of 58.4 years and included 231 patients (28.8%) ≥65 
years of age. The majority were white (66.4%), and most were obese, with body mass index ≥30 kg/m2 (53.6%). 
For the entire cohort, mean duration of T2DM was 6.3 years, with approximately 20% having a diabetes duration 
≥10 years. At baseline, mean HbA1c was 7.7%, mean FPG was 8.9 mmol/L (160 mg/dL), and the mean 
metformin dose was 1829 mg/day. Baseline characteristics in the per-protocol analysis set (n = 677) were similar 
to those for the randomized study cohort (N = 801). 
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Table 1. Patient demographics and key baseline characteristics 
 Saxagliptin + metformin 
(n = 403) 
Sitagliptin + metformin  
(n = 398) 
Total  
(N = 801) 
Age (years)    
Mean (SD) 58.8 (10.1) 58.1 (10.5) 58.4 (10.3) 
≥65 years, n (%) 111 (27.5) 120 (30.2) 231 (28.8) 
Gender, n (%)    
Male 190 (47.1) 202 (50.8) 392 (48.9) 
Female 213 (52.9) 196 (49.2) 409 (51.1) 
Race, n (%)    
White 273 (67.7) 259 (65.1) 532 (66.4) 
Asian 34 (8.4) 40 (10.1) 74 (9.2) 
Black/African American 29 (7.2) 30 (7.5) 59 (7.4) 
American Indian/Alaskan native 25 (6.2) 25 (6.3) 50 (6.2) 
Other 42 (10.4) 44 (11.1) 86 (10.7) 
Geographic region, n (%)    
Europe 208 (51.6) 201 (50.5) 409 (51.1) 
Latin America 126 (31.3) 127 (31.9) 253 (31.6) 
South Africa 69 (17.1) 70 (17.6) 139 (17.4) 
Body mass index (kg/m2)    
Mean (SD) 31.1 (5.3) 30.9 (5.5) 31.0 (5.4) 
≥30 kg/m2, n (%) 222 (55.1) 207 (52.0) 429 (53.6) 
Duration of type 2 diabetes mellitus (years)    
Mean (SD) 6.3 (5.0) 6.3 (4.7) 6.3 (4.9) 
Duration ≥5 years, n (%) 220 (54.6) 204 (51.3) 424 (52.9) 
Duration ≥10 years, n (%) 73 (18.1) 85 (21.4) 158 (19.7) 
Baseline parameters, mean (SD)    
Glycated haemoglobin (%) 7.7 (1.0) 7.7 (0.9) 7.7 (0.9) 
Fasting plasma glucose (mmol/L) 8.9 (2.5) 8.9 (2.4) 8.9 (2.5) 
Fasting insulin (pmol/L) 90.8 (82.3) 84.4 (77.4) 87.6 (79.9) 
Metformin dose (mg/day)    
Mean (SD) 1831.5 (463.5) 1826.2 (480.7) 1828.8 (471.8)
≥1500-<2000, n (%) 233 (57.8) 245 (61.6) 478 (59.7) 
≥2000-<2500, n (%) 99 (24.6) 76 (19.1) 175 (21.8) 
≥2500-<3000, n (%) 45 (11.2) 45 (11.3) 90 (11.2) 
≥3000, n (%) 25 (6.2) 31 (7.8) 56 (7) 
Not reported 1 (0.2) 1 (0.3) 2 (0.2) 
SD, standard deviation. 
 
Table 2. Statistical analysis of the changes in HbA1c from baseline to week 18 after the addition of saxagliptin or 
sitagliptin to metformin therapy in the per-protocol analysis set 
 Saxagliptin + metformin 
(n = 334) 
Sitagliptin + metformin 
(n = 343) 
Mean (SE) HbA1c at baseline (%) 7.68 (0.052) 7.69 (0.047) 
Mean (SE) HbA1c at week 18 (%) 7.16 (0.052) 7.07 (0.051) 
Adjusted change from baseline HbA1c (%)   
    Mean (SE) -0.52 (0.039) -0.62 (0.038) 
    Two-sided 95% confidence interval -0.60, -0.45 -0.69, -0.54 
Difference in adjusted change from baseline HbA1c 
versus sitagliptin plus metformin (%) 
  
    Mean (SE) 0.09 (0.055) - 
    Two-sided 95% confidence interval -0.01, 0.20 - 
HbA1c, glycated haemoglobin; SE, standard error. 
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Figure 2. Mean (±SE) glycated haemoglobin (HbA1c) values at each visit during the double-blind treatment 




Based on the per-protocol analysis set, the addition of saxagliptin or sitagliptin to metformin therapy produced 
similar decreases in mean HbA1c from baseline to week 18 (Table 2). Mean HbAlc declined from 7.68 to 7.16% 
in the saxagliptin plus metformin group; the adjusted mean (±SE) change was -0.52% (±0.039) (95% CI, -0.60 to 
-0.45%). Similarly, mean HbA1c declined from 7.69 to 7.07% in the sitagliptin plus metformin group, an 
adjusted mean change of -0.62% (±0.038) (95% CI, -0.69 to -0.54%). The difference between groups in the 
adjusted mean change from baseline HbA1c was 0.09% (95% CI, -0.01 to 0.20%). The upper limit of this 95% CI 
was below the predefined criterion for noninferiority of <0.3%. Thus, saxagliptin added to metformin was 
noninferior to sitagliptin added to metformin. The results of the per-protocol analysis were confirmed in the full 
cohort analysis set, in which the adjusted mean change in HbA1c from baseline to week 18 was -0.42% for 
saxagliptin plus metformin and -0.59% for sitagliptin plus metformin. In this data set, the difference between 
groups in the adjusted mean change from baseline HbA1c was 0.17% (95% CI, 0.06-0.28%), with the upper limit 
of the 95% CI also below the predefined noninferiority criterion of <0.3%. Median changes from baseline to 
week 18 in HbA1c values in the full cohort analysis set were -0.50% in both treatment groups. The reduction in 
HbA1c seen after the addition of saxagliptin or sitagliptin to metformin therapy was achieved within the first 8 
weeks and was maintained until the end of the study in both groups (Figure 2). 
The proportion of patients achieving therapeutic glycaemic responses was similar in the two treatment groups 
(Figure 3). Overall, 105 of 399 patients (26.3%) who received saxagliptin plus metformin compared with 114 of 
392 patients (29.1%) who received sitagliptin plus metformin achieved an HbA1c ≤ 6.5% at week 18. The 
difference between treatments (saxagliptin versus sitagliptin) in glycaemic response rate was -2.8% (95% CI, -
9.0 to 3.5%). For those with an HbA1c ≥ 7.0% at baseline, 97 of 294 patients (33.0%) in the saxagliptin plus 
metformin group and 117 of 299 patients (39.1%) in the sitagliptin plus metformin group achieved an HbA1c < 
7.0% at week 18, a -6.1% difference between groups (95% CI, -13.8 to 1.6%). 
Improvements in glycaemic control were also observed as decreases in FPG from baseline to week 18 (Table 3). 
Adding saxagliptin or sitagliptin to metformin therapy produced adjusted mean changes in FPG of -0.60mmol/L 
(-10.8 mg/dL) and -0.90 mmol/L (-16.2 mg/dL), respectively. The mean difference was 0.30 mmol/L (5.42 
mg/dL); 95% CI, 0.08-0.53 mmol/L (1.37-9.47 mg/dL). There were no apparent differences between treatment 
groups for the changes from baseline in fasting insulin, glucagon, proinsulin, or C-peptide (Table 3). Similarly, 
the small improvement in β-cell function, as measured by the change from   baseline   in   homeostasis   model   
assessment-2β, did   not   differ   between   the   two   treatment   groups (Table 3). 
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Figure 3. Proportion of patients achieving glycaemic response with glycated haemoglobin (HbA1c) ≤ 6.5% at 
week 18, and proportion of patients with baseline HbA1c ≥ 7.0% achieving HbA1c < 7.0% at week 18. Saxagliptin 
(SAXA) + metformin (MET) HbA1c ≤ 6.5%, n = 399; sitagliptin (SITA) + MET HbA1c ≤ 6.5%, n = 392; SAXA + 
MET HbA1c ≤ 7.0%, n = 294; SITA + MET HbA1c ≤ 7.0%, n = 299 
 
Table 3. Changes from baseline to week 18 in secondary efficacy variables in the full analysis cohort 
 Saxagliptin + metformin 
(n = 397) 
Sitagliptin + metformin  
(n = 392) 
Mean difference 
between groupsa
Fasting plasma glucose (mmol/L)    
Mean (SE) at baseline 8.86 (0.127) 8.89 (0.122) - 
Mean (SE) at week 18 8.27 (0.111) 7.99 (0.103) - 
Adjusted mean change (SE) from baseline -0.60 (0.081) -0.90 (0.081) 0.30 (0.115) 
   95% CI -0.75, -0.44 -1.06, -0.74 0.08, 0.53 
Fasting insulin (µmol/L) n = 354 n = 357  
Mean (SE) at baseline 92.7 (4.50) 82.9 (4.08) - 
Mean (SE) at week 18 89.4 (3.35) 82.7 (3.32) - 
Adjusted mean change (SE) from baseline -0.5 (2.79) -3.0 (2.78) 2.5 (3.94) 
   95% CI -5.9, 5.0 -8.4, 2.5 -5.2, 10.2 
Fasting glucagon (pmol/L) n = 343 n = 339  
Mean (SE) at baseline 22.0 (0.49) 22.0 (0.53) - 
Mean (SE) at week 18 21.9 (0.49) 21.0 (0.43) - 
Adjusted mean change (SE) from baseline -0.1 (0.39) -1.0 (0.39) 0.9 (0.55) 
   95% CI -0.9, 0.7 -1.8, -0.2 -0.2, 2.0 
Fasting proinsulin (pmol/L) n = 359 n = 358  
Mean (SE) at baseline 29.1 (1.86) 25.0 (1.20) - 
Mean (SE) at week 18 26.0 (1.52) 22.4 (1.07) - 
Adjusted mean change (SE) from baseline -2.4 (0.87) -3.4 (0.87) 1.0 (1.23) 
   95% CI -4.1, -0.7 -5.1, -1.7 -1.4, 3.4 
Fasting C-peptide (nmol/L) n = 332 n = 342  
Mean (SE) at baseline 1.01 (0.031) 0.94 (0.028) - 
Mean (SE) at week 18 1.04 (0.028) 0.96 (0.027) - 
Adjusted mean change (SE) from baseline 0.05 (0.022) 0.01 (0.021) 0.04 (0.030) 
   95% CI 0.00, 0.09 -0.03, 0.05 -0.02, 0.10 
Homeostasis model assessment-2β (%) n = 324 n = 334  
Mean (SE) at baseline 69.6 (2.23) 63.5 (1.97) - 
Mean (SE) at week 18 79.8 (2.43) 77.4 (2.08) - 
Adjusted mean change (SE) from baseline 11.0(1.61) 13.1 (1.58) -2.2 (2.26) 
   95% CI 7.8, 14.1 10.0, 16.3 -6.6, 2.3 
CI, confidence interval; SE, standard error. 
aDifference in adjusted mean change from baseline to week 18 with saxagliptin + metformin versus sitagliptin + metformin. 
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Safety 
The safety profile of the combination of saxagliptin plus metformin was similar to that of sitagliptin plus 
metformin. Overall, the incidence of reported adverse events during the 18-week treatment period was 47.1% 
among patients treated with saxagliptin plus metformin and 47.2% among those given sitagliptin plus metformin 
(Table 4). In general, the incidence and types of adverse events when classified by system organ class or 
preferred term according to the Medical Dictionary for Regulatory Activities were similar between treatment 
groups. The most common adverse events were influenza, urinary tract infection, and nasopharyngitis (Table 4). 
Overall, nine patients in each treatment group discontinued due to  adverse  events.  By system  organ  class,   
the  most common adverse events were infections and infestations (occurring in 25.1% of patients in each 
treatment group), gastrointestinal disorders (occurring in 9.2 versus 10.6% of patients in the saxagliptin and 
sitagliptin groups, respectively), and musculoskeletal and connective tissue disorders (7.2 versus 8.3%). 
Twelve serious adverse events (7 in the saxagliptin group and 5 in the sitagliptin group) were reported during the 
study, but only 3 of these events (1 in the saxagliptin group and 2 in the sitagliptin group) were considered by the 
investigator to be related to study treatment. In the saxagliptin group, a woman 59 years of age developed 
hyperglycaemia after treatment for 41 days, leading to discontinuation of study treatment. In the sitagliptin 
group, a woman 56 years of age had hypoglycaemia after 113 days of treatment (physical activity was a 
contributing factor), and a woman 46 years of age had hypoglycaemia after 75 days of treatment (no known 
contributing factor). Study drug was interrupted in the second case. The patients with treatment-related serious 
adverse events recovered within 1-3 days. No deaths occurred during the study period. Two cardiovascular-
related adverse events were reported in the sitagliptin group (one myocardial ischaemia and one transient 
ischaemic attack); none were reported in the saxagliptin group. 
 
Table 4. Safety profile 
Incidence, n (%) Saxagliptin + metformin 
(n = 403) 
Sitagliptin + metformin  
(n = 398) 
Any adverse event 190 (47.1) 188 (47.2) 
   Treatment-related 21 (5.2) 30 (7.5) 
Any serious adverse event 7 (1.7) 5 (1.3) 
   Treatment-related 1 (0.2) 2 (0.5) 
Deaths 0 0 
Discontinuations due to adverse events 9 (2.2) 9 (2.3) 
Most common adverse events (≥2%)   
   Influenza 23 (5.7) 23 (5.8) 
   Urinary tract infection 23 (5.7) 21 (5.3) 
   Nasopharyngitis 16 (4.0) 16 (4.0) 
   Headache 11 (2.7) 9 (2.3) 
   Diarrhoea 10 (2.5) 10 (2.5) 
   Upper respiratory tract infection 9 (2.2) 4 (1.0) 
   Back pain 7 (1.7) 10 (2.5) 
   Nausea 4 (1.0) 9 (2.3) 
   Arthralgia 2 (0.5) 10 (2.5) 
 
Hypoglycaemic adverse events occurred in 13 patients (3.2%) in the saxagliptin plus metformin group and in 11 
patients (2.8%) in the sitagliptin plus metformin group. Most of the events were mild in intensity, although one 
patient in the sitagliptin group had a major hypoglycaemic event according to the Committee for Proprietary 
Medicinal Products classification. According to serious adverse events classified by system organ class or 
preferred term, two patients in the sitagliptin plus metformin group experienced hypoglycaemia. 
The numbers of patients with skin disorders, based on either total adverse events in system organ class Skin and 
Subcutaneous Disorders or skin-related adverse events considered by investigators to be related to treatment, 
were slightly higher in the sitagliptin group compared with the saxagliptin group, but the differences were not 
considered clinically relevant (2% for saxagliptin versus 5% for sitagliptin, and 0.7% for saxagliptin versus 1.5% 
for sitagliptin, respectively). Further, there were no clinically relevant mean changes from baseline haematology 
or clinical chemistry values, vital signs, electrocardiogram, or physical examination findings in either group. 
Body weight declined from baseline by a mean of 0.4 kg in both treatment groups. 
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DISCUSSION 
This study met its primary objective by showing that adding saxagliptin to metformin was noninferior to adding 
sitagliptin to metformin in reducing HbA1c from baseline to week 18 in the per-protocol population, a finding 
confirmed in the full cohort analysis set. The two treatment groups were also comparable in the proportions of 
patients achieving a therapeutic glycaemic response (defined as HbA1c ≤ 6.5%), and among those with baseline 
HbA1c ≥ 7.0% achieving a glycaemic response of HbA1c < 7.0%. With the exception of modest differences in the 
FPG reduction, changes in all other secondary efficacy variables were similar between treatment groups. 
Therefore, the results of this study show that adding either saxagliptin or sitagliptin to a stable dose of metformin 
therapy similarly improves glycaemic control in patients with T2DM inadequately controlled by metformin 
alone. 
Safety profiles were also similar with the addition of saxagliptin or sitagliptin to metformin therapy. The 
incidence and types of adverse events were comparable between treatment groups, and the frequency of serious 
adverse events was low with each treatment. Notably, the incidence of hypoglycaemic events was about 3% in 
each group, and in all but one case (in the sitagliptin group), the events were minor hypoglycaemic events or 
events suggestive of hypoglycaemia according to the Committee for Proprietary Medicinal Products 
classification. While skin adverse reactions were more frequent in the sitagliptin group versus the saxagliptin 
group, the difference was not considered clinically relevant. Both DPP-4 inhibitors were well tolerated as 
reflected in the high rates of study completion (>90%) and the low rates of discontinuation due to adverse events 
(≤2%). 
The results of the present study are similar to those of previous randomized, placebo-controlled clinical trials in 
which DPP-4 inhibitors were added to stable metformin therapy or used as initial therapy in combination with 
metformin [20]. The addition of saxagliptin to ongoing metformin therapy, compared with the addition of 
placebo, produced an adjusted mean change in HbA1c of -0.83% from a baseline of 8.1%, and it allowed more 
than twice as many patients to achieve the goal of HbAlc < 7.0% (43.5 versus 16.6%) [7]. Similarly, the addition 
of 100 mg/day sitagliptin to ongoing metformin therapy produced an adjusted mean change in HbA1c of 
approximately -0.7% from a baseline value of 8.0%, and -1.0% from a baseline of 9.3%. Compared with 
placebo, the addition of sitagliptin allowed approximately 20-30% more patients to achieve HbA1c levels <7.0% 
[11,21,22]. In a 1-year noninferiority trial comparing 100 mg/day sitagliptin with glipizide as add-on therapy to 
metformin, changes in HbA1c from baseline (7.5%) were -0.67% at week 52 in both groups, with 63% of patients 
achieving HbA1c < 7.0% with sitagliptin and 59% with glipizide [23]. In another 1-year noninferiority trial, 50 
mg vildagliptin twice daily added to metformin reduced HbA1c from baseline (7.3%) comparably to glimepiride 
added to metformin (-0.44 versus -0.53% at week 52), resulting in a similar proportion of patients reaching a 
target HbA1c of <7.0% with vildagliptin and glimepiride (54.1 and 55.5%, respectively) [24]. In these studies, the 
tolerability of the DPP-4 inhibitors was generally comparable to that of placebo, with low incidences of 
hypoglycaemic events and small decreases in body weight; in addition, safety profiles were consistent with those 
observed with saxagliptin and sitagliptin in the present study, and further support the noninferiority of 
saxagliptin to sitagliptin [7,11]. Previous head-to-head trials have shown a much lower incidence of 
hypoglycaemic episodes with either sitagliptin [23] or vildagliptin [24] compared with sulphonylureas such as 
glipizide or glimepiride when added to metformin monotherapy. 
Obesity is prevalent among patients with T2DM and the issue of weight control warrants further attention [25]. 
The absence of weight gain despite a significant improvement in glycaemic control represents an advantage of 
DPP-4 inhibitors compared with other oral glucose-lowering agents such as sulphonylureas [23,24] or 
thiazolidinediones such as pioglitazone [26,27]. 
The primary limitation of this study is similar to that of other noninferiority trials: the exclusion of a comparator 
placebo group (in this case, placebo plus metformin). However, previously conducted placebo-controlled trials 
with both saxagliptin in combination with metformin [7] and sitagliptin in combination with metformin [11] 
provided necessary context for the design and conduct of this study. For example, as noted, the doses of each 
DPP-4 inhibitor used in this study - 5 mg/day saxagliptin and 100 mg/day sitagliptin - were previously shown to 
significantly improve glycaemic control as measured by decreases in HbA1c and FPG compared with placebo, 
and by the higher proportions of patients achieving glycaemic goals compared with placebo within the setting of 
add-on therapy to metformin [7,11]. In these earlier placebo-controlled trials, adding a DPP-4 inhibitor to 
metformin reduced HbA1c by -0.65 to -1% compared with placebo [7,11,21,22]. HbA1c was increased slightly or 
remained unchanged in the placebo groups of these studies. Thus, the improvements in HbA1c achieved in the 
present study are consistent with the previous trials, especially when baseline HbA1c is taken into account in the 
analysis [28]. In addition, the safety profiles of the DPP-4 inhibitors can be placed into context on the basis of 
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the previous placebo-controlled trials with saxagliptin or sitagliptin in combination with metformin. These 
earlier placebo-controlled trials showed that when added to metformin, DPP-4 inhibitors were well tolerated, and 
that their safety profiles were generally comparable to that of placebo [7,11,21,22]. Therefore, the adverse event 
profiles of saxagliptin and sitagliptin in the present study are consistent with the overall safety and tolerability of 
the DPP-4 inhibitor class observed in respective placebo-controlled studies. 
In conclusion, the present study establishes the noninferiority of saxagliptin to sitagliptin when added to 
metformin therapy. The present study also showed that adding saxagliptin to stable metformin therapy was 
effective in lowering HbA1c and was generally well tolerated in patients with T2DM whose glycaemia was 
inadequately controlled by metformin alone. Moreover, the addition of saxagliptin or sitagliptin to ongoing 
metformin treatment allowed clinically significant proportions of patients to achieve the glycaemic goal of 
HbA1c < 7.0% without causing hypoglycaemia or weight gain. These data provide further evidence supporting 
the clinical utility of the DPP-4 inhibitor-metformin combination. 
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